Publications by authors named "Heimo Stroissnig"

Claim this Profile
R
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
Steven R Feldman, Nataliya Reznichenko, Fausto Berti, Paul Duijzings, Ruth Ruffieux, Heimo Stroissnig

Expert Opin Biol Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Interchangeability of AVT02 and Humira in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.
Steven R Feldman, Richard Kay, Nataliya Reznichenko, Joanna Sobierska, Roshan Dias, Heimo Stroissnig

BioDrugs· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
Christopher Wynne, Paul Hamilton, Kristi McLendon, Heimo Stroissnig, Matthew Smith

Expert Opin Investig Drugs· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults.
Christopher Wynne, Christian Schwabe, Heimo Stroissnig, Roshan Dias, Joanna Sobierska

Expert Opin Biol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe.
Nemanja Damjanov, Nana Kirvalidze, Nana Kurashvili, Fausto Berti, Matjaz Steiger, Heimo Stroissnig

Expert Opin Biol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint analysis of PK and immunogenicity outcomes using factorization model - a powerful approach for PK similarity study.
Halimu N Haliduola, Fausto Berti, Heimo Stroissnig, Eric Guenzi, Hendrik Otto

BMC Med Res Methodol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
Christopher Wynne, Christian Schwabe, Charlotte Lemech, Heimo Stroissnig, Roshan Dias

Expert Opin Investig Drugs· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
Steven R Feldman, Nataliya Reznichenko, Grazyna Pulka, Külli Kingo, George Galdava, Heimo Stroissnig

BioDrugs· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue.
Thijs van Iersel, Heimo Stroissnig, Peter Giesen, Johan Wemer, Karin Wilhelm-Ogunbiyi

Thromb Haemost· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis